Table 2.
Characteristic of the study population at cohort inclusion, stratified by participation in the third phase cross-sectional study visit.
| Characteristics | Phase 1 (N=308) | Phase 3 | P valuea | ||||
|
|
|
Participatingb (n=147) | Nonparticipating (n=161) |
|
|||
| Male, n (%) | 259 (84.1) | 119 (81.0) | 140 (87.0) | .15 | |||
| Age (years), median (IQR) | 40 (35-45) | 40 (35-44) | 39 (35-45) | .93 | |||
| Alcohol consumption >1 glass/day (n=295), n (%) | 176 (59.7) | 87 (61.2) | 89 (58.2) | .59 | |||
| BMI (kg/m2; n=291), n (%) | .94 | ||||||
| Underweight (16.5-18.5) | 16 (5.5) | 8 (5.8) | 8 (5.3) |
|
|||
| Normal (18.5-25.0) | 221 (75.9) | 105 (75.5) | 116 (76.3) |
|
|||
| Overweight (25-30) | 46 (15.8) | 23 (16.6) | 23 (15.1) |
|
|||
| Moderate or severe obesity (>30) | 8 (2.8) | 3 (2.2) | 5 (3.3) |
|
|||
| Estimated HIV infection duration (years), median (IQR) | 9.9 (3.6-14.0) | 9.4 (3.8-13.1) | 10.2 (3.6-14.6) | .29 | |||
| AIDS-defining illness, n (%) | 79 (25.6) | 30 (20.4) | 49 (30.4) | .04 | |||
| CD4+ T cell count (per mm3), median (IQR) | 400 (269-555) | 404 (283-557) | 399 (264-554) | .83 | |||
| Nadir CD4+ T cell count (per mm3; n=271), median (IQR) | 212 (103-325) | 212 (107-309) | 215 (90-344) | .81 | |||
| ARTc experienced at inclusion, n (%) | 251 (81.8) | 122 (83.0) | 129 (80.6) | .59 | |||
| Detectable HIV RNA (>50 copies/mL), n (%) | 145 (47.2) | 64 (43.5) | 81 (50.6) | .21 | |||
| HIV-RNA viral load (log10 copies/mL)d, median (IQR) | 3.90 (2.59-4.44) | 3.91 (2.48-4.41) | 3.89 (2.87-4.50) | .68 | |||
| From country of high endemicity, n (%) | 86 (27.9) | 47 (32.0) | 39 (24.2) | .16 | |||
| Estimated HBVe infection duration (years), median (IQR) | 6.1 (2.2-10.8) | 7.3 (2.8-11.2) | 5.3 (2.2-10.4) | .14 | |||
| HBV DNA >60 IU/mL, n (%) | 238 (77.2) | 113 (76.9) | 124 (77.5) | .90 | |||
| HBV DNA viral load (log10 IU/mL)d, median (IQR) | 4.26 (2.55-6.58) | 3.39 (2.36-6.58) | 4.68 (2.66-6.69) | .12 | |||
| HBeAgf positive, n (%) | 160 (52.0) | 73 (49.7) | 87 (54.0) | .44 | |||
| HBV genotype ( n =170), n (%) | .18 | ||||||
| A | 105 (61.8) | 51 (68.0) | 54 (56.8) |
|
|||
| B | 1 (0.6) | 0 (0.0) | 1 (1.1) |
|
|||
| D | 17 (10.0) | 7 (9.3) | 10 (10.5) |
|
|||
| E | 19 (11.2) | 8 (10.7) | 11 (11.6) |
|
|||
| G | 19 (11.2) | 5 (6.7) | 14 (14.7) |
|
|||
| Mixed A/D or A/G | 9 (5.3) | 4 (5.3) | 5 (5.3) |
|
|||
| Precore W28stop mutation (n=164), n (%) | 47 (28.7) | 18 (24.7) | 29 (31.9) | .31 | |||
| Lamivudine-resistance mutations (n=146), n (%) | 97 (66.4) | 42 (64.6) | 55 (67.9) | .67 | |||
| Other viral hepatitis, n (%) | .48 | ||||||
|
|
Anti-HCVg positive serology | 19 (6.2) | 9 (6.1) | 10 (6.2) |
|
||
|
|
Anti-HDVh positive serology | 12 (3.9) | 6 (4.1) | 6 (3.7) |
|
||
|
|
Anti-HCV and anti-HDV positive serology | 12 (3.9) | 3 (2.0) | 9 (5.6) |
|
||
aSignificance was determined using the Kruskal-Wallis test for continuous variables and Pearson χ² test or Fisher exact test for categorical variables.
bParticipating patients were defined as those signing written informed consent and completing the third phase cross-sectional study visit. All characteristics reported in the table are from data collected at the inclusion visit of the French HIV-HBV cohort (2002-2003).
cART: antiretroviral therapy.
dAmong patients with detectable viral loads.
eHBV: hepatitis B virus.
fHBeAg: hepatitis B e virus antigen.
gHCV: hepatitis C virus.
hHDV: hepatitis D virus.